← Evidence map

ArticleJournal of clinical medicine2025

Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%).

Fedja Djordjevic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%). | OpenQuestion